Myra Medical, a Campbell, Calif.-based newly formed Shifamed portfolio company advancing surgical devices to enable maximum intraocular pressure reduction, raised $3.16m in seed funding.
Backers included Shifamed accredited angel investors.
The company intends to use the funds to advance product development and pre-clinical programs.
Myra Medical is evolving the surgical device landscape with a novel technology that aims to provide physicians and patients with an effective platform to safely enable maximum intraocular pressure (IOP) reduction while reducing the risk of hypotony, improving treatment for moderate to advanced glaucoma patients
Shifamed also announced the appointments of Robert Chang to serve as Myra Medical’s Chief Executive Officer and Tracy Valorie, seasoned ophthalmology executive, to serve as strategic advisor to the company.
Robert Chang joins Myra Medical with over 30 years of executive and medical device development experience. Most recently, Mr. Chang was the Co-Founder, President, CEO and Director at MVRx, Inc. Prior to this, Chang served as Executive Vice President and Chief Technology Officer of Sadra Medical, a legacy company of Shifamed, acquired by Boston Scientific Corporation. Prior to his time with Sadra, Chang co-founded Ample Medical, serving as their President, CEO and Director.
Tracy Valorie advises Myra Medical with over 25 years of experience and most recently serving as the Senior Vice President, General Manager of the U.S. Pharmaceutical and Surgical businesses at Bausch + Lomb. Previously, Ms. Valorie was the Commercial Lead of Ophthalmology at Pfizer, with responsibility for multiple global Ophthalmology brands and commercial development of mid-stage portfolio and long-range strategic planning.
Founded by serial entrepreneur Amr Salahieh, Shifamed is a highly specialized medical innovation hub focused on developing solutions that accelerate time to market, reduce risk, increase impact, and forge a path toward a world where patients are able to lead longer, healthier lives.
加州坎贝尔医疗公司 Myra Medical 。以新成立的 Shifamed 投资组合公司为基础，推进手术器械以最大限度地降低眼压，筹集了316万美元的种子资金。
Myra Medical 正在利用一项新技术发展外科设备领域，旨在为医生和患者提供一个有效的平台，以安全地实现最大眼内压（眼压（IOP））的降低，同时降低低通气量的风险，改善中、晚期青光眼患者的治疗
Shifamed 公司还宣布任命 Robert Chang 担任 Myra Medical 首席执行官和经验丰富的眼科高管 Tracy Valorie 担任公司战略顾问。
Robert Chang 加入 Myra Medical 拥有30多年的执行和医疗设备开发经验。最近， Chang 先生是 MVRx , Inc .的共同创始人、总裁、首席执行官和董事。在此之前， Chang 先生曾担任 Sadra Medical 的执行副总裁和首席技术官， Sadra Medical 是 Shifamed 的一家遗留公司，被波士顿科学（Boston Scientific）公司收购。在加入 Sadra 之前， Chang 共同创立 Ample Medical ，担任总裁、首席执行官和董事。
Tracy Valorie 为 Myra Medical 提供咨询服务，拥有超过25年的经验，最近担任 Bausch + Lomb 的美国医药和外科业务高级副总裁、总经理。此前， Vallorie 女士曾担任辉瑞（Pfizer）公司眼科的商业主管，负责多个全球眼科学品牌以及中期组合和长期战略规划的商业开发。
Shifamed 由一系列企业家 Amr Salahie 创立，是一个高度专业化的医疗创新中心，致力于开发能够加快上市时间、降低风险、增加影响的解决方案，并为患者能够过上更长、更健康生活的世界铺平道路。